Sana biotechnology, inc. stockholder news: robbins llp reminds investors of the class action lawsuit against sana

San diego, march 26, 2025 (globe newswire) -- robbins llp reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired sana biotechnology, inc. (nasdaq: sana) securities between march 17, 2023 and november 4, 2024. sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system (“cns”) disorders, and b-cell-mediated autoimmune diseases.
SANA Ratings Summary
SANA Quant Ranking